5/3/2023 0 Comments Tessera therapeutics![]() Nextflow Tower also helped simplify the management of cloud resources. To boost productivity, Tessera decided to deploy Nextflow Tower from Seqera Labs - a management platform for Nextflow workflows designed to enable collaborative data analysis at scale. Today, most pipelines are implemented in Nextflow. Tessera Therapeutics began shifting to Nextflow for most of its analysis pipelines a few years ago. ![]() Gene Writer proteins can be delivered by RNA or DNA, and research teams extensively use RNASeq and a variety of other pipelines for analysis. Gene Writing holds the potential to become a new category in genetic medicine, building on recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy.ĭeveloping new therapeutics depends on their ability to identify and organize mobile genetic element sequences for multiple species from different genome databases and identify and prioritize promising protein and DNA signatures. ![]() Tessera Therapeutics are the innovators behind Gene Writing and Gene Rewriting, new biotechnologies designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, with the potential to treat and cure diseases at their source. By using Nextflow Tower from Seqera Labs to manage analysis pipelines, Tessera increased its analysis throughput and research productivity while simultaneously containing cloud spending by using resources more efficiently. SWFI is a minority-owned organization.Tessera Therapeutics are pioneers in a new category of genetic medicine and rely heavily on genomic analysis pipelines to identify promising new treatments. SWFI facilitates sovereign fund, pension, endowment, superannuation fund and central bank events around the world. Sovereign Wealth Fund Institute (SWFI) is a global organization designed to study sovereign wealth funds, pensions, endowments, superannuation funds, family offices, central banks and other long-term institutional investors in the areas of investing, asset allocation, risk, governance, economics, policy, trade and other relevant issues. Registration on or use of this site constitutes acceptance of our terms of use agreement which includes our privacy policy. All material subject to strictly enforced copyright laws. No affiliation or endorsement, express or implied, is provided by their use. Other third-party content, logos and trademarks are owned by their perspective entities and used for informational purposes only. Sovereign Wealth Fund Institute® and SWFI® are registered trademarks of the Sovereign Wealth Fund Institute. © 2008-2023 Sovereign Wealth Fund Institute. By changing any base pair to another, making small insertions or deletions, and writing entire genes into the genome, Gene Writing unlocks the potential to cure genetic diseases and create life-changing therapeutics in cardiovascular, oncological, neurodegenerative, and infectious diseases.Īltitude Life Science Ventures is a venture capital firm based in Kirkland, Washington that invests in early stage life science companies. Gene Writing is a new technology that has the ability to write therapeutic instructions into the genome to treat diseases at their source. Tessera Therapeutics was revealed publicly in July 2020 after years being incubated within Flagship Labs. The genetics company raised US$ 230 million in Series B funding from Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2, and the Qatar Investment Authority (QIA). Tessera Therapeutics is a Cambridge, Massachusetts-based programmable genetics startup founded by Flagship Pioneering. ![]() Sovereign Wealth Funds Back Gene Writing Company Tessera Therapeutics
0 Comments
Leave a Reply. |